Palbociclib for patients with hormone receptor positive / HER2-negative breast cancer that has recurred after surgical removal (POLAR)

IBCSG 59-19 POLAR

Coordinating investigator

Prof. Dr. med.
Stefan Paul
Aebi
Luzerner Kantonsspital
+41 41 205 58 60

For further information on the IBCSG 59-19 POLAR trial, please consult the IBCSG website.

Clinics

All trials